Stocks-QLGN-Qualigen Therapeutics Inc

QLGN Qualigen Therapeutics Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Qualigen Therapeutics Inc's revenues decreased by 11.85% and amounted to 4.98M. Net income decreased by 17.53% to -21.03M. Net assets decreased by 47.08% to 8.77M and EPS decreased from -0.61 to -4.85.
QLGN's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
26.96%
Net Profit Margin
-345.30%
Operating Margin
-312.10%
Return On Investment
-158.59%